CA2008304C - Dosage de la phosphatase alcaline des os - Google Patents

Dosage de la phosphatase alcaline des os Download PDF

Info

Publication number: CA2008304C
Authority: CA; Canada
Prior art keywords: bap; antibody; amount; labeled; monoclonal antibody
Prior art date: 1989-01-31
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Expired - Lifetime

Application number

CA002008304A

Other languages

English (en)

Other versions

CA2008304A1 (fr

Inventor

Craig S. Hill

Robert L. Wolfert

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Hybritech Inc

Original Assignee

Hybritech Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1989-01-31

Filing date

1990-01-23

Publication date

2001-03-27

1990-01-23 Application filed by Hybritech Inc filed Critical Hybritech Inc

1990-07-31 Publication of CA2008304A1 publication Critical patent/CA2008304A1/fr

2001-03-27 Application granted granted Critical

2001-03-27 Publication of CA2008304C publication Critical patent/CA2008304C/fr

2010-01-23 Anticipated expiration legal-status Critical

Status Expired - Lifetime legal-status Critical Current

Links

238000003556 assay Methods 0.000 title claims abstract description 61
102000002260 Alkaline Phosphatase Human genes 0.000 title claims abstract description 22
108020004774 Alkaline Phosphatase Proteins 0.000 title claims abstract description 22
210000000988 bone and bone Anatomy 0.000 title abstract description 10
238000000034 method Methods 0.000 claims description 66
239000012530 fluid Substances 0.000 claims description 46
239000000523 sample Substances 0.000 claims description 38
239000012528 membrane Substances 0.000 claims description 35
239000007787 solid Substances 0.000 claims description 31
102000004190 Enzymes Human genes 0.000 claims description 24
108090000790 Enzymes Proteins 0.000 claims description 24
239000000427 antigen Substances 0.000 claims description 20
102000036639 antigens Human genes 0.000 claims description 20
108091007433 antigens Proteins 0.000 claims description 20
210000004027 cell Anatomy 0.000 claims description 16
230000008569 process Effects 0.000 claims description 15
YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 claims description 14
239000013068 control sample Substances 0.000 claims description 13
210000004408 hybridoma Anatomy 0.000 claims description 13
239000000126 substance Substances 0.000 claims description 13
210000002966 serum Anatomy 0.000 claims description 12
229960002685 biotin Drugs 0.000 claims description 8
239000011616 biotin Substances 0.000 claims description 8
239000011859 microparticle Substances 0.000 claims description 8
230000002441 reversible effect Effects 0.000 claims description 8
235000020958 biotin Nutrition 0.000 claims description 7
230000002285 radioactive effect Effects 0.000 claims description 7
108090001008 Avidin Proteins 0.000 claims description 3
230000009260 cross reactivity Effects 0.000 claims description 3
108010090804 Streptavidin Proteins 0.000 claims description 2
210000004185 liver Anatomy 0.000 abstract description 7
102100031156 Prohibitin-2 Human genes 0.000 description 129
102100034798 CCAAT/enhancer-binding protein beta Human genes 0.000 description 66
239000011324 bead Substances 0.000 description 45
239000000243 solution Substances 0.000 description 22
229940088598 enzyme Drugs 0.000 description 17
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 16
239000002953 phosphate buffered saline Substances 0.000 description 15
239000003153 chemical reaction reagent Substances 0.000 description 14
XZKIHKMTEMTJQX-UHFFFAOYSA-N 4-Nitrophenyl Phosphate Chemical compound OP(O)(=O)OC1=CC=C([N+]([O-])=O)C=C1 XZKIHKMTEMTJQX-UHFFFAOYSA-N 0.000 description 12
239000000872 buffer Substances 0.000 description 12
239000002245 particle Substances 0.000 description 12
239000000758 substrate Substances 0.000 description 12
238000004458 analytical method Methods 0.000 description 11
230000000694 effects Effects 0.000 description 10
206010003445 Ascites Diseases 0.000 description 9
239000000975 dye Substances 0.000 description 9
238000005406 washing Methods 0.000 description 9
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 8
PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 8
231100000673 dose–response relationship Toxicity 0.000 description 8
239000000203 mixture Substances 0.000 description 8
230000003197 catalytic effect Effects 0.000 description 7
238000003127 radioimmunoassay Methods 0.000 description 7
239000012064 sodium phosphate buffer Substances 0.000 description 7
241000699666 Mus <mouse, genus> Species 0.000 description 6
241001494479 Pecora Species 0.000 description 6
239000004793 Polystyrene Substances 0.000 description 6
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 6
229920002223 polystyrene Polymers 0.000 description 6
102000004169 proteins and genes Human genes 0.000 description 6
108090000623 proteins and genes Proteins 0.000 description 6
238000000746 purification Methods 0.000 description 6
208000010191 Osteitis Deformans Diseases 0.000 description 5
208000027868 Paget disease Diseases 0.000 description 5
229920001213 Polysorbate 20 Polymers 0.000 description 5
239000008367 deionised water Substances 0.000 description 5
229910021641 deionized water Inorganic materials 0.000 description 5
230000002163 immunogen Effects 0.000 description 5
239000007788 liquid Substances 0.000 description 5
208000027202 mammary Paget disease Diseases 0.000 description 5
238000004519 manufacturing process Methods 0.000 description 5
-1 polyethylene Polymers 0.000 description 5
239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 5
235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 5
150000003839 salts Chemical class 0.000 description 5
108010015776 Glucose oxidase Proteins 0.000 description 4
239000004366 Glucose oxidase Substances 0.000 description 4
MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 4
LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 4
238000002820 assay format Methods 0.000 description 4
239000003599 detergent Substances 0.000 description 4
238000010790 dilution Methods 0.000 description 4
239000012895 dilution Substances 0.000 description 4
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
239000012153 distilled water Substances 0.000 description 4
238000001962 electrophoresis Methods 0.000 description 4
229940116332 glucose oxidase Drugs 0.000 description 4
235000019420 glucose oxidase Nutrition 0.000 description 4
239000011159 matrix material Substances 0.000 description 4
239000011148 porous material Substances 0.000 description 4
239000000047 product Substances 0.000 description 4
230000004044 response Effects 0.000 description 4
230000035945 sensitivity Effects 0.000 description 4
239000006228 supernatant Substances 0.000 description 4
229920002994 synthetic fiber Polymers 0.000 description 4
229920000936 Agarose Polymers 0.000 description 3
102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 description 3
108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 description 3
229920002684 Sepharose Polymers 0.000 description 3
HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
241000473945 Theria <moth genus> Species 0.000 description 3
238000013019 agitation Methods 0.000 description 3
239000002021 butanolic extract Substances 0.000 description 3
238000005119 centrifugation Methods 0.000 description 3
150000001875 compounds Chemical class 0.000 description 3
238000001514 detection method Methods 0.000 description 3
FRTGEIHSCHXMTI-UHFFFAOYSA-N dimethyl octanediimidate Chemical compound COC(=N)CCCCCCC(=N)OC FRTGEIHSCHXMTI-UHFFFAOYSA-N 0.000 description 3
201000010099 disease Diseases 0.000 description 3
230000009977 dual effect Effects 0.000 description 3
239000000284 extract Substances 0.000 description 3
239000011536 extraction buffer Substances 0.000 description 3
238000001914 filtration Methods 0.000 description 3
238000004128 high performance liquid chromatography Methods 0.000 description 3
238000013198 immunometric assay Methods 0.000 description 3
230000005764 inhibitory process Effects 0.000 description 3
239000000463 material Substances 0.000 description 3
201000008968 osteosarcoma Diseases 0.000 description 3
239000008188 pellet Substances 0.000 description 3
239000000843 powder Substances 0.000 description 3
239000011780 sodium chloride Substances 0.000 description 3
238000003756 stirring Methods 0.000 description 3
238000012360 testing method Methods 0.000 description 3
TXUICONDJPYNPY-UHFFFAOYSA-N (1,10,13-trimethyl-3-oxo-4,5,6,7,8,9,11,12,14,15,16,17-dodecahydrocyclopenta[a]phenanthren-17-yl) heptanoate Chemical compound C1CC2CC(=O)C=C(C)C2(C)C2C1C1CCC(OC(=O)CCCCCC)C1(C)CC2 TXUICONDJPYNPY-UHFFFAOYSA-N 0.000 description 2
AZQWKYJCGOJGHM-UHFFFAOYSA-N 1,4-benzoquinone Chemical compound O=C1C=CC(=O)C=C1 AZQWKYJCGOJGHM-UHFFFAOYSA-N 0.000 description 2
108091003079 Bovine Serum Albumin Proteins 0.000 description 2
229920002307 Dextran Polymers 0.000 description 2
108010001336 Horseradish Peroxidase Proteins 0.000 description 2
108010023244 Lactoperoxidase Proteins 0.000 description 2
102000045576 Lactoperoxidases Human genes 0.000 description 2
241001465754 Metazoa Species 0.000 description 2
206010035226 Plasma cell myeloma Diseases 0.000 description 2
241000276498 Pollachius virens Species 0.000 description 2
239000004698 Polyethylene Substances 0.000 description 2
SMWDFEZZVXVKRB-UHFFFAOYSA-N Quinoline Chemical compound N1=CC=CC2=CC=CC=C21 SMWDFEZZVXVKRB-UHFFFAOYSA-N 0.000 description 2
PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 2
UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
229910021626 Tin(II) chloride Inorganic materials 0.000 description 2
PNDPGZBMCMUPRI-XXSWNUTMSA-N [125I][125I] Chemical compound [125I][125I] PNDPGZBMCMUPRI-XXSWNUTMSA-N 0.000 description 2
238000002835 absorbance Methods 0.000 description 2
239000002253 acid Substances 0.000 description 2
239000002671 adjuvant Substances 0.000 description 2
239000012491 analyte Substances 0.000 description 2
239000008346 aqueous phase Substances 0.000 description 2
239000008366 buffered solution Substances 0.000 description 2
230000001413 cellular effect Effects 0.000 description 2
238000006243 chemical reaction Methods 0.000 description 2
VDQQXEISLMTGAB-UHFFFAOYSA-N chloramine T Chemical compound [Na+].CC1=CC=C(S(=O)(=O)[N-]Cl)C=C1 VDQQXEISLMTGAB-UHFFFAOYSA-N 0.000 description 2
238000012875 competitive assay Methods 0.000 description 2
230000002860 competitive effect Effects 0.000 description 2
239000012228 culture supernatant Substances 0.000 description 2
ATDGTVJJHBUTRL-UHFFFAOYSA-N cyanogen bromide Chemical compound BrC#N ATDGTVJJHBUTRL-UHFFFAOYSA-N 0.000 description 2
238000004090 dissolution Methods 0.000 description 2
238000001035 drying Methods 0.000 description 2
230000002255 enzymatic effect Effects 0.000 description 2
230000004927 fusion Effects 0.000 description 2
239000000499 gel Substances 0.000 description 2
239000011521 glass Substances 0.000 description 2
150000004676 glycans Chemical class 0.000 description 2
QRMZSPFSDQBLIX-UHFFFAOYSA-N homovanillic acid Chemical compound COC1=CC(CC(O)=O)=CC=C1O QRMZSPFSDQBLIX-UHFFFAOYSA-N 0.000 description 2
210000000987 immune system Anatomy 0.000 description 2
238000000338 in vitro Methods 0.000 description 2
238000000099 in vitro assay Methods 0.000 description 2
238000011534 incubation Methods 0.000 description 2
230000000366 juvenile effect Effects 0.000 description 2
229940057428 lactoperoxidase Drugs 0.000 description 2
208000019423 liver disease Diseases 0.000 description 2
239000003658 microfiber Substances 0.000 description 2
201000000050 myeloid neoplasm Diseases 0.000 description 2
239000000546 pharmaceutical excipient Substances 0.000 description 2
239000004033 plastic Substances 0.000 description 2
229920003023 plastic Polymers 0.000 description 2
229920000573 polyethylene Polymers 0.000 description 2
229920001282 polysaccharide Polymers 0.000 description 2
239000005017 polysaccharide Substances 0.000 description 2
239000002243 precursor Substances 0.000 description 2
238000002360 preparation method Methods 0.000 description 2
210000003625 skull Anatomy 0.000 description 2
229910052938 sodium sulfate Inorganic materials 0.000 description 2
235000011152 sodium sulphate Nutrition 0.000 description 2
241000894007 species Species 0.000 description 2
239000001119 stannous chloride Substances 0.000 description 2
235000011150 stannous chloride Nutrition 0.000 description 2
210000002303 tibia Anatomy 0.000 description 2
229960001479 tosylchloramide sodium Drugs 0.000 description 2
210000000689 upper leg Anatomy 0.000 description 2
YMXHPSHLTSZXKH-RVBZMBCESA-N (2,5-dioxopyrrolidin-1-yl) 5-[(3as,4s,6ar)-2-oxo-1,3,3a,4,6,6a-hexahydrothieno[3,4-d]imidazol-4-yl]pentanoate Chemical compound C([C@H]1[C@H]2NC(=O)N[C@H]2CS1)CCCC(=O)ON1C(=O)CCC1=O YMXHPSHLTSZXKH-RVBZMBCESA-N 0.000 description 1
GEYOCULIXLDCMW-UHFFFAOYSA-N 1,2-phenylenediamine Chemical compound NC1=CC=CC=C1N GEYOCULIXLDCMW-UHFFFAOYSA-N 0.000 description 1
PNDPGZBMCMUPRI-HVTJNCQCSA-N 10043-66-0 Chemical compound [131I][131I] PNDPGZBMCMUPRI-HVTJNCQCSA-N 0.000 description 1
KRQUFUKTQHISJB-YYADALCUSA-N 2-[(E)-N-[2-(4-chlorophenoxy)propoxy]-C-propylcarbonimidoyl]-3-hydroxy-5-(thian-3-yl)cyclohex-2-en-1-one Chemical compound CCC\C(=N/OCC(C)OC1=CC=C(Cl)C=C1)C1=C(O)CC(CC1=O)C1CCCSC1 KRQUFUKTQHISJB-YYADALCUSA-N 0.000 description 1
BFSVOASYOCHEOV-UHFFFAOYSA-N 2-diethylaminoethanol Chemical compound CCN(CC)CCO BFSVOASYOCHEOV-UHFFFAOYSA-N 0.000 description 1
JRBJSXQPQWSCCF-UHFFFAOYSA-N 3,3'-Dimethoxybenzidine Chemical compound C1=C(N)C(OC)=CC(C=2C=C(OC)C(N)=CC=2)=C1 JRBJSXQPQWSCCF-UHFFFAOYSA-N 0.000 description 1
102100031126 6-phosphogluconolactonase Human genes 0.000 description 1
108010029731 6-phosphogluconolactonase Proteins 0.000 description 1
CJIJXIFQYOPWTF-UHFFFAOYSA-N 7-hydroxycoumarin Natural products O1C(=O)C=CC2=CC(O)=CC=C21 CJIJXIFQYOPWTF-UHFFFAOYSA-N 0.000 description 1
238000013296 A/J mouse Methods 0.000 description 1
102100026189 Beta-galactosidase Human genes 0.000 description 1
208000006386 Bone Resorption Diseases 0.000 description 1
241000283707 Capra Species 0.000 description 1
OKTJSMMVPCPJKN-NJFSPNSNSA-N Carbon-14 Chemical compound [14C] OKTJSMMVPCPJKN-NJFSPNSNSA-N 0.000 description 1
201000009030 Carcinoma Diseases 0.000 description 1
NBSCHQHZLSJFNQ-GASJEMHNSA-N D-Glucose 6-phosphate Chemical compound OC1O[C@H](COP(O)(O)=O)[C@@H](O)[C@H](O)[C@H]1O NBSCHQHZLSJFNQ-GASJEMHNSA-N 0.000 description 1
FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
206010011878 Deafness Diseases 0.000 description 1
238000002965 ELISA Methods 0.000 description 1
VFRROHXSMXFLSN-UHFFFAOYSA-N Glc6P Natural products OP(=O)(O)OCC(O)C(O)C(O)C(O)C=O VFRROHXSMXFLSN-UHFFFAOYSA-N 0.000 description 1
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
108010018962 Glucosephosphate Dehydrogenase Proteins 0.000 description 1
SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 1
241000238631 Hexapoda Species 0.000 description 1
101000836873 Homo sapiens Nucleotide exchange factor SIL1 Proteins 0.000 description 1
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
108010093096 Immobilized Enzymes Proteins 0.000 description 1
108010044467 Isoenzymes Proteins 0.000 description 1
108060001084 Luciferase Proteins 0.000 description 1
239000005089 Luciferase Substances 0.000 description 1
KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
239000004472 Lysine Substances 0.000 description 1
102000013460 Malate Dehydrogenase Human genes 0.000 description 1
108010026217 Malate Dehydrogenase Proteins 0.000 description 1
229930195725 Mannitol Natural products 0.000 description 1
206010027476 Metastases Diseases 0.000 description 1
229920001410 Microfiber Polymers 0.000 description 1
102000016943 Muramidase Human genes 0.000 description 1
108010014251 Muramidase Proteins 0.000 description 1
241000699670 Mus sp. Species 0.000 description 1
108010062010 N-Acetylmuramoyl-L-alanine Amidase Proteins 0.000 description 1
206010028980 Neoplasm Diseases 0.000 description 1
GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
239000000020 Nitrocellulose Substances 0.000 description 1
239000004677 Nylon Substances 0.000 description 1
206010031149 Osteitis Diseases 0.000 description 1
229910019142 PO4 Inorganic materials 0.000 description 1
206010033892 Paraplegia Diseases 0.000 description 1
208000007542 Paresis Diseases 0.000 description 1
239000004743 Polypropylene Substances 0.000 description 1
206010041549 Spinal cord compression Diseases 0.000 description 1
229920002472 Starch Polymers 0.000 description 1
108010057517 Strep-avidin conjugated horseradish peroxidase Proteins 0.000 description 1
GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 1
YZCKVEUIGOORGS-NJFSPNSNSA-N Tritium Chemical compound [3H] YZCKVEUIGOORGS-NJFSPNSNSA-N 0.000 description 1
230000009471 action Effects 0.000 description 1
239000000654 additive Substances 0.000 description 1
238000005349 anion exchange Methods 0.000 description 1
239000002518 antifoaming agent Substances 0.000 description 1
230000000890 antigenic effect Effects 0.000 description 1
238000013459 approach Methods 0.000 description 1
238000013096 assay test Methods 0.000 description 1
239000000987 azo dye Substances 0.000 description 1
210000003719 b-lymphocyte Anatomy 0.000 description 1
230000008901 benefit Effects 0.000 description 1
108010005774 beta-Galactosidase Proteins 0.000 description 1
238000007413 biotinylation Methods 0.000 description 1
230000006287 biotinylation Effects 0.000 description 1
230000000903 blocking effect Effects 0.000 description 1
210000004369 blood Anatomy 0.000 description 1
239000008280 blood Substances 0.000 description 1
210000001124 body fluid Anatomy 0.000 description 1
239000010839 body fluid Substances 0.000 description 1
208000018339 bone inflammation disease Diseases 0.000 description 1
230000024279 bone resorption Effects 0.000 description 1
229940098773 bovine serum albumin Drugs 0.000 description 1
210000000481 breast Anatomy 0.000 description 1
150000001718 carbodiimides Chemical class 0.000 description 1
239000003054 catalyst Substances 0.000 description 1
239000001913 cellulose Substances 0.000 description 1
229920002678 cellulose Polymers 0.000 description 1
230000008859 change Effects 0.000 description 1
239000007795 chemical reaction product Substances 0.000 description 1
239000003795 chemical substances by application Substances 0.000 description 1
210000003109 clavicle Anatomy 0.000 description 1
239000011248 coating agent Substances 0.000 description 1
238000000576 coating method Methods 0.000 description 1
230000000052 comparative effect Effects 0.000 description 1
230000021615 conjugation Effects 0.000 description 1
238000007796 conventional method Methods 0.000 description 1
230000008878 coupling Effects 0.000 description 1
238000010168 coupling process Methods 0.000 description 1
238000005859 coupling reaction Methods 0.000 description 1
238000012258 culturing Methods 0.000 description 1
231100000895 deafness Toxicity 0.000 description 1
238000003745 diagnosis Methods 0.000 description 1
239000012470 diluted sample Substances 0.000 description 1
LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
208000035475 disorder Diseases 0.000 description 1
238000007823 electrophoretic assay Methods 0.000 description 1
238000010828 elution Methods 0.000 description 1
239000000839 emulsion Substances 0.000 description 1
238000001952 enzyme assay Methods 0.000 description 1
108010094102 enzymobeads Proteins 0.000 description 1
XJRPTMORGOIMMI-UHFFFAOYSA-N ethyl 2-amino-4-(trifluoromethyl)-1,3-thiazole-5-carboxylate Chemical compound CCOC(=O)C=1SC(N)=NC=1C(F)(F)F XJRPTMORGOIMMI-UHFFFAOYSA-N 0.000 description 1
238000002474 experimental method Methods 0.000 description 1
235000013861 fat-free Nutrition 0.000 description 1
239000012894 fetal calf serum Substances 0.000 description 1
GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 1
238000005194 fractionation Methods 0.000 description 1
239000003365 glass fiber Substances 0.000 description 1
239000008103 glucose Substances 0.000 description 1
208000016354 hearing loss disease Diseases 0.000 description 1
230000002440 hepatic effect Effects 0.000 description 1
102000052329 human SIL1 Human genes 0.000 description 1
210000002758 humerus Anatomy 0.000 description 1
210000004754 hybrid cell Anatomy 0.000 description 1
230000007062 hydrolysis Effects 0.000 description 1
238000006460 hydrolysis reaction Methods 0.000 description 1
238000003018 immunoassay Methods 0.000 description 1
238000002347 injection Methods 0.000 description 1
239000007924 injection Substances 0.000 description 1
230000000968 intestinal effect Effects 0.000 description 1
230000026045 iodination Effects 0.000 description 1
238000006192 iodination reaction Methods 0.000 description 1
229940044173 iodine-125 Drugs 0.000 description 1
230000001678 irradiating effect Effects 0.000 description 1
238000002955 isolation Methods 0.000 description 1
239000004816 latex Substances 0.000 description 1
229920000126 latex Polymers 0.000 description 1
230000031700 light absorption Effects 0.000 description 1
HWYHZTIRURJOHG-UHFFFAOYSA-N luminol Chemical compound O=C1NNC(=O)C2=C1C(N)=CC=C2 HWYHZTIRURJOHG-UHFFFAOYSA-N 0.000 description 1
229960000274 lysozyme Drugs 0.000 description 1
239000004325 lysozyme Substances 0.000 description 1
235000010335 lysozyme Nutrition 0.000 description 1
239000000594 mannitol Substances 0.000 description 1
235000010355 mannitol Nutrition 0.000 description 1
238000005259 measurement Methods 0.000 description 1
230000009401 metastasis Effects 0.000 description 1
235000013336 milk Nutrition 0.000 description 1
239000008267 milk Substances 0.000 description 1
210000004080 milk Anatomy 0.000 description 1
238000002156 mixing Methods 0.000 description 1
VYQNWZOUAUKGHI-UHFFFAOYSA-N monobenzone Chemical compound C1=CC(O)=CC=C1OCC1=CC=CC=C1 VYQNWZOUAUKGHI-UHFFFAOYSA-N 0.000 description 1
230000001537 neural effect Effects 0.000 description 1
229910017604 nitric acid Inorganic materials 0.000 description 1
229920001220 nitrocellulos Polymers 0.000 description 1
229920001778 nylon Polymers 0.000 description 1
230000003647 oxidation Effects 0.000 description 1
238000007254 oxidation reaction Methods 0.000 description 1
239000011236 particulate material Substances 0.000 description 1
239000013610 patient sample Substances 0.000 description 1
210000004197 pelvis Anatomy 0.000 description 1
239000012071 phase Substances 0.000 description 1
NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
239000010452 phosphate Substances 0.000 description 1
239000007981 phosphate-citrate buffer Substances 0.000 description 1
230000003169 placental effect Effects 0.000 description 1
229920002401 polyacrylamide Polymers 0.000 description 1
229920000058 polyacrylate Polymers 0.000 description 1
229920001155 polypropylene Polymers 0.000 description 1
229920000136 polysorbate Polymers 0.000 description 1
239000003755 preservative agent Substances 0.000 description 1
230000002335 preservative effect Effects 0.000 description 1
230000000750 progressive effect Effects 0.000 description 1
210000002307 prostate Anatomy 0.000 description 1
208000017497 prostate disease Diseases 0.000 description 1
239000012521 purified sample Substances 0.000 description 1
230000005855 radiation Effects 0.000 description 1
238000000163 radioactive labelling Methods 0.000 description 1
239000000700 radioactive tracer Substances 0.000 description 1
230000009257 reactivity Effects 0.000 description 1
230000009467 reduction Effects 0.000 description 1
PYWVYCXTNDRMGF-UHFFFAOYSA-N rhodamine B Chemical compound [Cl-].C=12C=CC(=[N+](CC)CC)C=C2OC2=CC(N(CC)CC)=CC=C2C=1C1=CC=CC=C1C(O)=O PYWVYCXTNDRMGF-UHFFFAOYSA-N 0.000 description 1
239000012266 salt solution Substances 0.000 description 1
238000012216 screening Methods 0.000 description 1
230000003248 secreting effect Effects 0.000 description 1
238000000926 separation method Methods 0.000 description 1
FZHAPNGMFPVSLP-UHFFFAOYSA-N silanamine Chemical class [SiH3]N FZHAPNGMFPVSLP-UHFFFAOYSA-N 0.000 description 1
229910052708 sodium Inorganic materials 0.000 description 1
239000011734 sodium Substances 0.000 description 1
235000017557 sodium bicarbonate Nutrition 0.000 description 1
229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
FYKDNWHPKQOZOT-UHFFFAOYSA-M sodium;dihydrogen phosphate;2-hydroxypropane-1,2,3-tricarboxylic acid Chemical compound [Na+].OP(O)([O-])=O.OC(=O)CC(O)(C(O)=O)CC(O)=O FYKDNWHPKQOZOT-UHFFFAOYSA-M 0.000 description 1
210000000952 spleen Anatomy 0.000 description 1
210000004989 spleen cell Anatomy 0.000 description 1
239000003381 stabilizer Substances 0.000 description 1
239000008107 starch Substances 0.000 description 1
235000019698 starch Nutrition 0.000 description 1
230000004936 stimulating effect Effects 0.000 description 1
QAOWNCQODCNURD-UHFFFAOYSA-N sulfuric acid Substances OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 1
239000013595 supernatant sample Substances 0.000 description 1
239000000725 suspension Substances 0.000 description 1
208000024891 symptom Diseases 0.000 description 1
239000012209 synthetic fiber Substances 0.000 description 1
239000012085 test solution Substances 0.000 description 1
ANRHNWWPFJCPAZ-UHFFFAOYSA-M thionine Chemical compound [Cl-].C1=CC(N)=CC2=[S+]C3=CC(N)=CC=C3N=C21 ANRHNWWPFJCPAZ-UHFFFAOYSA-M 0.000 description 1
239000001003 triarylmethane dye Substances 0.000 description 1
229910052722 tritium Inorganic materials 0.000 description 1
GPRLSGONYQIRFK-MNYXATJNSA-N triton Chemical compound [3H+] GPRLSGONYQIRFK-MNYXATJNSA-N 0.000 description 1
230000007306 turnover Effects 0.000 description 1
ORHBXUUXSCNDEV-UHFFFAOYSA-N umbelliferone Chemical compound C1=CC(=O)OC2=CC(O)=CC=C21 ORHBXUUXSCNDEV-UHFFFAOYSA-N 0.000 description 1
HFTAFOQKODTIJY-UHFFFAOYSA-N umbelliferone Natural products Cc1cc2C=CC(=O)Oc2cc1OCC=CC(C)(C)O HFTAFOQKODTIJY-UHFFFAOYSA-N 0.000 description 1
210000002700 urine Anatomy 0.000 description 1
238000010200 validation analysis Methods 0.000 description 1
239000006226 wash reagent Substances 0.000 description 1

Classifications

- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/573—Immunoassay; Biospecific binding assay; Materials therefor for enzymes or isoenzymes
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S435/00—Chemistry: molecular biology and microbiology
- Y10S435/975—Kit
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S436/00—Chemistry: analytical and immunological testing
- Y10S436/807—Apparatus included in process claim, e.g. physical support structures
- Y10S436/808—Automated or kit

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Immunology (AREA)
Engineering & Computer Science (AREA)
Molecular Biology (AREA)
Biomedical Technology (AREA)
Chemical & Material Sciences (AREA)
Hematology (AREA)
Urology & Nephrology (AREA)
Physics & Mathematics (AREA)
General Physics & Mathematics (AREA)
Cell Biology (AREA)
Food Science & Technology (AREA)
Medicinal Chemistry (AREA)
Biotechnology (AREA)
Analytical Chemistry (AREA)
Biochemistry (AREA)
General Health & Medical Sciences (AREA)
Microbiology (AREA)
Pathology (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)
Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Peptides Or Proteins (AREA)
Investigating Or Analysing Biological Materials (AREA)
Saccharide Compounds (AREA)
Dental Preparations (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Steroid Compounds (AREA)

CA002008304A 1989-01-31 1990-01-23 Dosage de la phosphatase alcaline des os Expired - Lifetime CA2008304C (fr)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US30452189A	1989-01-31	1989-01-31
US07/304,521		1989-01-31

Publications (2)

Publication Number	Publication Date
CA2008304A1 CA2008304A1 (fr)	1990-07-31
CA2008304C true CA2008304C (fr)	2001-03-27

Family

ID=23176884

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
CA002008304A Expired - Lifetime CA2008304C (fr)	1989-01-31	1990-01-23	Dosage de la phosphatase alcaline des os

Country Status (10)

Country	Link
US (2)	US5525473A (fr)
EP (1)	EP0381450B1 (fr)
JP (1)	JP3055789B2 (fr)
AT (1)	ATE160021T1 (fr)
AU (1)	AU635518B2 (fr)
CA (1)	CA2008304C (fr)
DE (1)	DE69031662T2 (fr)
DK (1)	DK0381450T3 (fr)
ES (1)	ES2110408T3 (fr)
GR (1)	GR3025816T3 (fr)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CA2008304C (fr) *	1989-01-31	2001-03-27	Craig S. Hill	Dosage de la phosphatase alcaline des os
US6201109B1 (en)	1993-01-13	2001-03-13	Dade Behring Marburg Gmbh	Assay for bone alkaline phosphatase
US6303325B1 (en)	1998-05-29	2001-10-16	Dade Behring Inc.	Method for detecting analytes
GB9812290D0 (en) *	1998-06-09	1998-08-05	Univ Nottingham	Back pain diagnosis
SE0103072D0 (sv) *	2001-09-17	2001-09-17	Pharmacia Diagnostics Ab	Multi-analyte assay device with multi-spot detection zone
JP4517353B2 (ja) *	2004-11-02	2010-08-04	日東紡績株式会社	ＩｇＡ結合性アルカリ性ホスファターゼ６の測定方法およびそれに用いるキット
KR20090115133A (ko) *	2007-02-02	2009-11-04	노파르티스 아게	골-관련 장애를 치료하기 위한 스클레로스틴 결합 파트너의 조절물질
US20130116131A1 (en)	2011-11-08	2013-05-09	Caldera Health Limited	Methods and materials for the diagnosis of prostate cancers
US8658166B2 (en)	2011-11-08	2014-02-25	Caldera Health Limited	Methods and materials for the diagnosis of prostate cancers
US8658164B2 (en)	2011-11-08	2014-02-25	Caldera Health Limited	Methods and materials for the diagnosis of prostate cancers
US8632971B2 (en)	2011-11-08	2014-01-21	Caldera Health Limited	Methods and materials for determining the efficacy of prostate cancer therapies
CN103412120A (zh) *	2013-09-03	2013-11-27	天津朗赛生物科技有限公司	人体血液中铁蛋白和骨碱性磷酸酶联合检测试纸及其制备方法
CN103412123A (zh) *	2013-09-03	2013-11-27	天津朗赛生物科技有限公司	骨碱性磷酸酶检测试纸及其制备方法
CN103675282B (zh) *	2013-11-27	2016-01-20	新昌县美迪生物科技有限公司	骨源性碱性磷酸酶定量检测试剂盒及其用途
CN114088626B (zh) *	2021-11-16	2022-08-26	国家食品安全风险评估中心	一种鉴定巴氏杀菌乳的方法及检测系统

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4302536A (en) *	1978-08-15	1981-11-24	Longenecker Robert W	Colorimetric immunoassay process
US4376110A (en) *	1980-08-04	1983-03-08	Hybritech, Incorporated	Immunometric assays using monoclonal antibodies
DE3420926A1 (de) *	1984-06-05	1985-12-05	Boehringer Mannheim Gmbh, 6800 Mannheim	Verfahren und reagenz zur differenzierten bestimmung von isoenzymen der alkalischen phosphatase sowie hierzu geeigneter monoklonaler antikoerper
US4740468A (en) *	1985-02-14	1988-04-26	Syntex (U.S.A.) Inc.	Concentrating immunochemical test device and method
TW203120B (fr) *	1985-10-04	1993-04-01	Abbott Lab
US4912033A (en) *	1985-11-14	1990-03-27	Washington University	Creatine kinase MB determination method
US4916056A (en) *	1986-02-18	1990-04-10	Abbott Laboratories	Solid-phase analytical device and method for using same
US5087573A (en) *	1988-03-02	1992-02-11	University Of Kansas	Monoclonal antibody against bone alkaline phosphatase
CA2008304C (fr) *	1989-01-31	2001-03-27	Craig S. Hill	Dosage de la phosphatase alcaline des os

1990
- 1990-01-23 CA CA002008304A patent/CA2008304C/fr not_active Expired - Lifetime
- 1990-01-25 AU AU48818/90A patent/AU635518B2/en not_active Expired
- 1990-01-30 ES ES90300959T patent/ES2110408T3/es not_active Expired - Lifetime
- 1990-01-30 JP JP2021913A patent/JP3055789B2/ja not_active Expired - Lifetime
- 1990-01-30 AT AT90300959T patent/ATE160021T1/de not_active IP Right Cessation
- 1990-01-30 EP EP90300959A patent/EP0381450B1/fr not_active Expired - Lifetime
- 1990-01-30 DE DE69031662T patent/DE69031662T2/de not_active Expired - Lifetime
- 1990-01-30 DK DK90300959T patent/DK0381450T3/da active
1994
- 1994-05-05 US US08/239,185 patent/US5525473A/en not_active Expired - Lifetime
1995
- 1995-06-02 US US08/458,740 patent/US5589574A/en not_active Expired - Lifetime
1997
- 1997-12-30 GR GR970403466T patent/GR3025816T3/el unknown

Also Published As

Publication number	Publication date
GR3025816T3 (en)	1998-03-31
ES2110408T3 (es)	1998-02-16
EP0381450A3 (fr)	1991-09-18
DE69031662T2 (de)	1998-03-05
DE69031662D1 (de)	1997-12-11
US5589574A (en)	1996-12-31
AU635518B2 (en)	1993-03-25
CA2008304A1 (fr)	1990-07-31
US5525473A (en)	1996-06-11
AU4881890A (en)	1990-08-09
ATE160021T1 (de)	1997-11-15
DK0381450T3 (da)	1998-07-27
JPH02259570A (ja)	1990-10-22
EP0381450B1 (fr)	1997-11-05
JP3055789B2 (ja)	2000-06-26
EP0381450A2 (fr)	1990-08-08

Legal Events

Date	Code	Title	Description
1996-08-09	EEER	Examination request
2010-01-23	MKEX	Expiry

Publication	Publication Date	Title
US5750355A (en)	1998-05-12	Methods for selectively detecting perinuclear anti-neutrophil cytoplasmic antibody of ulcerative colitis or primary sclerosing cholangitis
US5202234A (en)	1993-04-13	Myocardial infarction immunoassay
JP3486413B2 (ja)	2004-01-13	前立腺特異抗原の免疫検定法
US4469787A (en)	1984-09-04	Immunoassay involving soluble complex of second antibody and labeled binding protein
US6326159B1 (en)	2001-12-04	Receptors for immune complexes
CA2008304C (fr)	2001-03-27	Dosage de la phosphatase alcaline des os
EP0166623A2 (fr)	1986-01-02	Test-sandwich à anticorps lectine
US4513088A (en)	1985-04-23	Assay for monoclonal antibody against surface Ig of a human B cell tumor
WO1985000663A1 (fr)	1985-02-14	Analyse immunometrique utilisant des anticorps polyclonaux et monoclonaux et kit d'analyse
US4489167A (en)	1984-12-18	Methods and compositions for cancer detection
EP0535162B1 (fr)	1995-03-29	Analyse de variantes d'analytes
US4665018A (en)	1987-05-12	Methods and test kit for diagnosing/monitoring cancer in humans
US4729961A (en)	1988-03-08	Process for the detection and assay by erythroadsorption
US6942977B1 (en)	2005-09-13	Immunoassays for determining vitamin b12, and reagents and kits therefor
US5009996A (en)	1991-04-23	Two site cross-reaction immunometric sandwich assay method
US5990274A (en)	1999-11-23	Cyclosporine derivatives and uses thereof
JPH0580053A (ja)	1993-03-30	ヒト子宮体癌細胞の免疫化学的検出方法
WO1987002779A1 (fr)	1987-05-07	Analyse de liaison de la conjonction idiotypique-antigenique
CA2110019C (fr)	2006-01-24	Immunodetection de la vitamine b12, reactifs et trousses
US5001052A (en)	1991-03-19	Immunoassay for FHAP and antibody useful therewith
EP0138946A1 (fr)	1985-05-02	Méthodes de monitorage de la situation cancéreuse chez les humains.
CA2047298A1 (fr)	1992-01-19	Dosage immunologique utilise pour le diagnostic de l'infarctus du myocarde
WO1983001118A1 (fr)	1983-03-31	Systeme de detection d'anticorps moncloniques
JPS62238463A (ja)	1987-10-19	プラスミン―α２プラスミンインヒビター複合体の測定方法
JPWO1996028733A1 (ja)	1998-04-28	肝臓由来のアルギナーゼに特異的な抗体およびその用途